

**BQ.10.2016**

**BEYOND-USE DATE (BUD)** studies provide crucial information on the quality and durability of compounded preparations.

This quarterly only releases the newest results of our BUD studies conducted in collaboration with renowned institutions:

- Hospital for Sick Children
- University of British Columbia
- University of Montreal
- University of Colorado
- University of Connecticut
- University of Western Sydney

### Unique Features and Benefits of Our BUD Studies:

- Utilize **stability-indicating** methods
- Use **dye-free** vehicles and target 90 days
- Provide stability data in **plastic syringes**, and **plastic** and **glass bottles**
- Test both forms of API: **commercial drug** and **pure powder**
- Perform stability testing at different temperatures (between 4°C and 25°C)
- Involve commonly and uncommonly compounded actives
- Are published in peer-reviewed journals
  - Canadian Journal of Hospital Pharmacy (CJHP)
  - International Journal of Pharmaceutical Compounding (IJPC)
  - Journal of Pharmacy Practice and Research (JPPR)

Accurate results ensure that a medication has maintained its compounded dosage.

#### Did you know?

The results of our studies led to the implementation of MEDISCA's **dye-free** oral vehicles at many healthcare establishments!

### Extended BUD Stability Studies



| ACETAZOLAMIDE<br>25 mg/mL              | ORAL MIX        |         |             |         |
|--|-----------------|---------|-------------|---------|
|  | COMMERCIAL DRUG |         | PURE POWDER |         |
|  | 5°C             | 25°C    | 5°C         | 25°C    |
| Amber PET Bottle                       | 90 days         | 90 days | 90 days     | 90 days |
| PreciseDose™ Dispenser (Clear Syringe) | 90 days         | 90 days | 90 days     | 90 days |



| ACETAZOLAMIDE<br>25 mg/mL              | ORAL MIX SF     |         |             |         |
|--|-----------------|---------|-------------|---------|
|  | COMMERCIAL DRUG |         | PURE POWDER |         |
|  | 5°C             | 25°C    | 5°C         | 25°C    |
| Amber PET Bottle                       | 90 days         | 90 days | 90 days     | 90 days |
| PreciseDose™ Dispenser (Clear Syringe) | 90 days         | 90 days | 90 days     | 90 days |

Less than 10% loss at 95% confidence interval.

\*Publication pending in Journal of Pediatric Pharmacology and Therapeutics (JPPT)

**BQ.10.2016**


| HYDROXYCHLOROQUINE SULFATE<br>25 mg/mL | ORAL MIX        |         | ORAL MIX SF |         |
|--|-----------------|---------|-------------|---------|
|  | COMMERCIAL DRUG |         |             |         |
|  | 4°C             | 21°C    | 4°C         | 21°C    |
| Amber PET Bottle                       | 90 days         | 90 days | 90 days     | 90 days |
| PreciseDose™ Dispenser (Amber Syringe) | 90 days         | 90 days | 90 days     | 90 days |

Less than 10% loss at 95% confidence interval.

\*Publication pending in International Journal of Pharmaceutical Compounding (IJPC)



| METRONIDAZOLE<br>50 mg/mL              | ORAL MIX        |         |             |         |
|--|-----------------|---------|-------------|---------|
|  | COMMERCIAL DRUG |         | PURE POWDER |         |
|  | 4°C             | 25°C    | 4°C         | 25°C    |
| Amber PET Bottle                       | 90 days         | 90 days | 90 days     | 90 days |
| PreciseDose™ Dispenser (Amber Syringe) | 90 days         | 90 days | N/A         | N/A     |



| METRONIDAZOLE<br>50 mg/mL              | ORAL MIX SF     |         |             |         |
|--|-----------------|---------|-------------|---------|
|  | COMMERCIAL DRUG |         | PURE POWDER |         |
|  | 4°C             | 25°C    | 4°C         | 25°C    |
| Amber PET Bottle                       | 90 days         | 90 days | 90 days     | 90 days |
| PreciseDose™ Dispenser (Amber Syringe) | 90 days         | 90 days | 90 days     | 90 days |

Less than 10% loss at 95% confidence interval.

\*Publication pending.



| VANCOMYCIN<br>50 mg/mL                 | ORAL SYRUP                  |         |             |      |
|--|-----------------------------|---------|-------------|------|
|  | COMMERCIAL DRUG: INJECTABLE |         | PURE POWDER |      |
|  | 4°C                         | 25°C    | 4°C         | 25°C |
| Amber PET Bottle                       | 90 days                     | 36 days | N/A         | N/A  |
| PreciseDose™ Dispenser (Amber Syringe) | 90 days                     | 30 days | N/A         | N/A  |

Less than 10% loss at 95% confidence interval.

\*Publication pending.



Over 20  
 Oral Base Stability Studies  
 Completed

